Gilead Sciences to present at three major healthcare conferences in September

0 min read | Published on 27 Aug 2026, 02:10 AM |Updated on 27 Aug 2026, 02:10 AM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Gilead Sciences executives will present at three investor conferences in September 2026
Sessions are scheduled with Wells Fargo, Cantor, and Morgan Stanley
Live webcasts and 30-day replays will be available on the company's investor site

*this image is generated using AI for illustrative purposes only.

Gilead Sciences (NASDAQ: GILD) announced that its executives will present at three upcoming investor conferences in September 2026. The presentations aim to provide updates on the company's business outlook and strategic initiatives.

Conference Schedule

The company scheduled its appearances across three major financial institutions over two weeks. The events are listed below:

Conference	Date	Time (Eastern)
Wells Fargo Annual Healthcare Conference	September 9, 2026	11:00 am
Cantor Global Healthcare Conference	September 10, 2026	10:55 am
Morgan Stanley Global Healthcare Conference	September 15, 2026	10:45 am

Accessing the Presentations

Investors can access live webcasts of these sessions via the company's investor relations page at investors.gilead.com. Replays of the presentations will remain available for at least 30 days following each event.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company focused on preventing and treating life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Headquartered in Foster City, California, the company operates in more than 35 countries worldwide.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific strategic initiatives or pipeline updates is Gilead expected to highlight during these September 2026 conferences?

How might the market react to Gilead's business outlook presented at these events, particularly regarding its HIV and oncology portfolios?

Are there any anticipated regulatory milestones or clinical trial results for Gilead's key assets that could be discussed in late 2026?

Gilead Sciences delivers 15.54% annualized return over five years

0 min read | Published on 25 Aug 2026, 03:51 AM |Updated on 25 Aug 2026, 03:51 AM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Gilead Sciences posted a 15.54% average annual return over five years
The stock outperformed the market by 4.4% on an annualized basis
A $1,000 investment five years ago is now worth $2,054.32
Market capitalization stands at $179.70 billion

*this image is generated using AI for illustrative purposes only.

Gilead Sciences (NASDAQ: GILD) generated an average annual return of 15.54% over the past five years, outperforming the broader market by 4.4% on an annualized basis.

The company currently holds a market capitalization of $179.70 billion. Based on a stock price of $144.92 at the time of writing, an initial investment of $1,000 made five years ago would be worth $2,054.32 today.

Performance Overview

The data highlights the impact of compounded returns on long-term capital growth. The total return calculation includes price appreciation over the specified period.

Metric	Value
Annualized Return	15.54%
Market Outperformance	4.4%
Current Market Cap	$179.70 billion
Current Share Price	$144.92
5-Year Investment Growth	$1,000 to $2,054.32

What the Numbers Show

The divergence between the company's annualized return of 15.54% and its market outperformance of 4.4% implies that the benchmark market index returned approximately 11.14% annually over the same period. This spread underscores Gilead's relative strength against broader market movements during this timeframe.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

Can Gilead Sciences sustain its 15.54% annualized return trajectory given the potential expiration of key patent protections in its HIV and hepatitis portfolios?

How might the company's recent strategic acquisitions, such as ImmunoGen, impact its future revenue growth and market capitalization relative to current levels?

What role will Gilead's expanding oncology pipeline play in offsetting potential declines in its legacy antiviral drug sales over the next five years?